文献速递主动脉疾病

使用INCRAFT装置行腹主动脉瘤腔内修复术后十年单中心结局

Ten-year single-center outcomes following endovascular repair for abdominal aortic aneurysm using the INCRAFT device.
PubMed 文献 · J Vasc Surg · 2024-03-13

单中心回顾性队列研究报告2012至2013年监管试验中使用INCRAFT装置行EVAR的30例腹主动脉瘤患者10年以上结局,中位随访125个月,动脉瘤相关死亡为0%,但囊体增长见于36.7%患者,再干预豁免率从5年89.0%降至10年60.9%,晚期开放转换豁免率从5年100%降至10年70.8%。

要点

  • 中位随访125个月,动脉瘤相关死亡为0%,全因死亡豁免率5年82.9%、10年75.3%。
  • 囊体增长见于11例(36.7%),其中6例最终需晚期开放转换。
  • 再干预豁免率5年89.0%、10年60.9%,晚期开放转换豁免率5年100%、10年70.8%。

核心结论

  • INCRAFT支架移植物的长期结局显示无动脉瘤相关死亡,但囊体增长在整个随访期间持续发生,导致后期再干预率相对较高,这凸显了终身术后监测和必要时适当再干预的重要性。

研究设计与样本

  • 单中心回顾性队列研究,纳入2012至2013年监管试验中所有使用INCRAFT装置行EVAR的患者30例,平均年龄71.8±7.7岁,EVAR时中位动脉瘤直径54.5 mm(四分位距53-56.8 mm)。

主要发现

  • 中位随访125个月(四分位距98-131个月),5年随访率100%、10年随访率96.7%;动脉瘤相关死亡为0%,全因死亡豁免率5年82.9%、10年75.3%。
  • 再干预见于10例患者共15次手术;囊体增长见于11例(36.7%),其中6例最终需晚期开放转换,5例行人造血管补片包裹术并保留支架移植物,1例行开放手术修复并移除内移植物。
  • 1例发生晚期破裂,因Ia型内漏在69个月时导致破裂,开放修复成功;再干预豁免率5年89.0%、10年60.9%,晚期开放转换豁免率5年100%、10年70.8%。
  • EVAR术后30天内无患者发生主要不良事件或手术相关并发症;所有患者均在局部麻醉下经皮成功植入INCRAFT装置,且所有腹主动脉瘤均按装置使用说明治疗。

临床怎么用

  • 作者认为,INCRAFT支架移植物长期结局显示无动脉瘤相关死亡,但囊体增长持续发生且后期再干预率相对较高,凸显了终身术后监测和必要时适当再干预的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to report the long-term outcomes beyond 10 years of endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms using the low-profile INCRAFT device. METHODS: This was a single-center, retrospective cohort study of all patients undergoing EVAR using the INCRAFT device as part of the regulatory trial between 2012 and 2013. Primary endpoint was aneurysm-related death. Secondary endpoints were all-cause death, reintervention, late open conversion, and aneurysm status (shrinkage, stable, and growth). RESULTS: Thirty patients with a mean age of 71.8 ± 7.7 years were included in this study. The median aneurysm diameter at EVAR was 54.5 mm (interquartile range, 53-56.8 mm). All abdominal aortic aneurysms in this study were treated following the device's instructions for use. At index EVAR, the INCRAFT device was successfully implanted in all patients using a percutaneous approach under local anesthesia. No patients experienced major adverse events or procedure-related complications 30 days after EVAR. During the median follow-up of 125 months (interquartile range, 98-131 months) with follow-up rates of 100% at 5 years and 96.7% at 10 years, aneurysm-related mortality was 0%, and freedom from all-cause mortality was 82.9% at 5 years and 75.3% at 10 years. Reintervention was required in 10 patients with 15 procedures. Sac growth was observed in 11 patients (36.7%), six of whom eventually required late open conversion; five of these patients underwent open aneurysmorrhaphy with stent graft preservation, and one underwent open surgical repair with endograft explantation. Late rupture was identified in one case, where type Ia endoleak led to rupture at 69 months, and open repair was successfully performed. Freedom from reintervention was 89.0% at 5 years but declined to 60.9% at 10 years; freedom from late open conversion was 100% at 5 years but declined to 70.8% at 10 years. CONCLUSIONS: Long-term outcomes of the INCRAFT stent graft showed no aneurysm-related deaths. However, sac growth occurred persistently throughout the follow-up period, resulting in a relatively high rate of reinterventions in the later periods, which highlights the importance of lifelong postoperative surveillance and appropriate reinterventions when indicated.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Ozawa H, Ohki T, Shukuzawa K, et al. Ten-year single-center outcomes following endovascular repair for abdominal aortic aneurysm using the INCRAFT device. J Vasc Surg. 2024. PMID: 38485069. doi:10.1016/j.jvs.2024.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。